NEW YORK, NY, USA I August 14, 2025 I Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being ...

FALLS CHURCH, VA, USA I August 13, 2025 I Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing next-generation therapies for weight management and metabolic health, ...

HONG KONG, China I August 10, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study ...

Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.

Hazard Ratios and Improvements in Median PFS are Unprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) In the trial, the gedatolisib triplet demonstrated a statistically significant and clinically ...

SAN DIEGO, CA, USA I July 21, 2025 I Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the completion ...

LEXINGTON, MA, USA I July 17, 2025 I Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat ...

BASEL, Switzerland I June 15, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory ...

MONTREAL, Canada I July 02, 2025 I Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has ...

CAMBRIDGE, MA, USA I June 21, 2025 I MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of ...

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required ...

SAN DIEGO, CA, USA I June 02, 2025 I Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that the company has nominated a lead ...